key: cord-0766971-dctehdpe
authors: Peña, Mónica; Ampuero, Manuel; Garcés, Carlos; Gaggero, Aldo; García, Patricia; Velasquez, María Soledad; Luza, Ricardo; Alvarez, Pía; Paredes, Fabio; Acevedo, Johanna; Farfán, Mauricio J.; Solari, Sandra; Soto-Rifo, Ricardo; Valiente-Echeverría, y Fernando
title: Performance of SARS-CoV-2 rapid antigen test compared with real-time RT-PCR in asymptomatic individuals
date: 2021-05-01
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.04.087
sha: 4238817d3b9c4dbc3b019773ad15335e6e8111e1
doc_id: 766971
cord_uid: dctehdpe

Screening, testing and contact tracing plays a pivotal role in the control of COVID-19 pandemic. To carry out this strategy it is necessary to increase the testing capacity. Here, we compared a SARS-CoV-2 rapid antigen test (RAT) and RT-PCR in 842 asymptomatic individuals from Tarapacá, Chile. We report a sensitivity of 69.86%, a specificity of 99.61%, PPV of 94.44% and NPP of 97.22% with Ct values (Ct > 27) that were significantly higher among individuals with false-negative RAT. These results support the fact that RAT might have a significant impact in the identification of asymptomatic carriers in areas that lack suitable laboratories to perform SARS-CoV-2 real-time RT-PCR diagnostics, or the results take more than 24-48 hours, as well as zones with high traffic of individuals, such as border/customs, airports, interregional bus, train stations or in any mass testing campaign requiring rapid results.

Given the increase in cases of SARS-CoV-2 infections worldwide, there is a need for a reliable rapid diagnostic test in addition to existing gold standard real-time RT-PCR. Rapid antigen tests J o u r n a l P r e -p r o o f (RAT) for SARS-CoV-2 can be performed onsite in mass testing, are inexpensive compared to real-time RT-PCR, do not require specific and expensive equipment and the results are available within 15 minutes (CDC), which could serve to evaluate chains of infection and their interruption.

A recent meta-analysis revealed that the average sensitivity and specificity of the RAT for SARS-CoV-2 was 56.2% and 99.5%, respectively . Up to date, most of these validations were carried out in symptomatic individuals or using samples previously collected (Cerutti et al., 2020 , Kruttgen et al., 2021 , Porte et al., 2020 , Weitzel et al., 2020 , Yamayoshi et al., 2020 . In contrast, onsite test validation studies in asymptomatic individuals to support the use of RAT in mass testing and epidemiological surveillance are limited (Jakobsen et al., 2021 , Mina et al., 2020 , Pollock et al., 2021 , Schildgen et al., 2021 , Toptan et al., 2020 . In this work, we performed an in-mass comparison of a RAT and the real-time RT-PCR test in asymptomatic individuals from a Chilean region.

Sample collection was coordinated by a specialized team from SEREMI de Salud Tarapacá. Two nasopharyngeal swabs (NSS) samples from asymptomatic individuals were collected by health care workers at Iquique city, Tarapacá Region, Chile between January 14 th and January 17 th , 2021, where the prevalence of SARS-CoV-2 infection was 11% according to data provided by the Chilean Ministry of Health (MINSAL). Taking into consideration that the expected prevalence of positive cases for COVID-19 in asymptomatic individuals can vary from 8 to 12% and establishing a sampling error of 1.5% and a type I error of 5%, then the minimum sample size required was 864 ± 69,7. All participants completed a questionnaire and provided information on demographic characteristics, current and past (14 days) symptoms, and recent exposure to people with COVID-guidelines. The second swab was preserved in specimen transport medium and transported at 4 °C to Laboratorio Médico Bioclinic and Hospital Regional de Iquique for RNA extraction and RT-PCR testing.

The SD Biosensor, Inc. Antigen Test (Republic of Korea, Catalog number 9901-NCOV-01G) is a rapid lateral flow immunoassay for the qualitative detection of SARS-CoV-2 specific antigens present in the human nasopharynx with sensitivity of 96.52% and specificity of 99.68% (SARS-CoV-2 Rapid Antigen Test Package Insert 2020-08, V 1.0). According to the manufacturer, the results are available within 30 min and all necessary reagents to perform the assay are provided.

The assay kits are stable when stored at 2-30 °C. Interval at 95% (GraphPad Prism version 9.0.1).

We evaluated the performance of the SARS-CoV-2 RAT (SD Biosensor, Inc. Republic of Korea,) compared with the real-time RT-PCR for SARS-CoV-2 detection among asymptomatic individuals at Iquique city, Tarapacá Region, Chile. The sampling was carried out in seven testing sites corresponding to i) workers (n=56; 6.7%), ii) sanitary residence (n=239; 28.4%), and iii) general public (n=547; 65%). Overall, 854 individuals were included (mean age: 36.67 years, SD: Figure 1A ). Next, we determined the k-means clustering J o u r n a l P r e -p r o o f analysis to find clusters in an iterative way using the Ct value of viral gene N (Cerutti et al., 2020) .

We identified three clusters: c1=16.87 (n=31, strongly positive), c2=24.5 (n=30, moderately positive) and c3=31.67 (n=12, weakly positive), where 96.77% (30/31) of the samples with low Ct value also tested positive for RAT ( Figure 1B, cluster 1) while the 66.6% (20/30) of the samples with medium Ct value also tested positive for RAT ( Figure 1B, cluster 2) . In contrast, only 8.33%

(1/12) of the samples with high Ct value tested positive for RAT ( Figure 1B, cluster 3) . Only 3

RATs positive and SARS CoV-2 real-time RT-PCR negative samples were identified (Table 1 ).

To control COVID-19 pandemic, improvement of SARS-CoV-2 diagnosis with easy, rapid, and cost-efficient approaches is urgently required. As of April 2021, more than 170 assays are on the market (FINDdx) and few have been extensively validated. Recently, the second iteration of a Cochrane living review summarized the accuracy of multiple RATs. The average sensitivity reported in symptomatic individuals from 37 evaluations was 72.0% (95% CI: 63.7% to 79.0%) while that in asymptomatic individuals from 12 evaluations was 58.1% (95% CI: 40.2% to 74.1%) (Dinnes et al., 2021) . The SD Biosensor RAT (Inc., Republic of Korea) manufacturer reported a higher sensitivity (96.52 %; 95 % CI: 91.33 to 99.04 %) obtained in prospective, randomized, single blinded studies conducted in Brazil and India in symptomatic and asymptomatic individuals (SARS-CoV-2 Rapid Antigen Test Package Insert 2020-08, V 1.0). In addition, a mass screening campaign in Catalonia (North-East Spain) evaluated four RATs in a cohort of 286 asymptomatic individuals. The sensitivity of each was 38·6% for Abbott assay, 51·5% for Siemens, 45·5% for Lepu and 43.6% for Roche (the same used in this study) with 83.3% in specimens with Ct < 30 (Baro et al., 2021) . Our study comprises asymptomatic individuals in three different contexts with an 8.64% prevalence of SARS-CoV-2 infection. In agreement with the Center of Disease Control Ct values (Ct > 27), which can be related to lower viral loads and less infectiousness in general (Bullard et al., 2020 , Singanayagam et al., 2020 . Given the high predictive values in asymptomatic individuals and the fast test result implying faster tracing of infected individuals, these results support and provide policymakers with evidence that RAT might have a significant role in COVID-19 screening, testing and contact tracing strategy to control COVID-19 pandemic in i) areas that lack suitable laboratories to perform SARS-CoV-2 real -time RT-PCR diagnostics, ii) areas where results take more than 24-48 hours, iii) areas with high traffic of individuals, such as border/customs, airports, interregional bus and train stations or in any mass testing campaign requiring rapid results. J o u r n a l P r e -p r o o f

Performance characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a head-tohead benchmark comparison

Predicting infectious SARS-CoV-2 from diagnostic samples

COVID-19): interim guidance for antigen testing for SARS-CoV-2

Urgent need of rapid tests for SARS CoV-2 antigen detection: Evaluation of the SD-Biosensor antigen test for SARS-CoV-2

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

Detection of SARS-CoV-2 infection by rapid antigen test in comparison with RT-PCR in a public setting

Comparison of the SARS-CoV-2 Rapid antigen test to the real star Sars-CoV-2 RT PCR kit

Rethinking Covid-19 Test Sensitivity -A Strategy for Containment

Performance and Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-throughput Drive-through Community Testing Site in Massachusetts

Evaluation of a novel antigenbased rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples

A Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19

Limits and Opportunities of SARS-CoV-2 Antigen Rapid Tests: An Experienced-Based Perspective

Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19

Evaluation of a SARS-CoV-2 rapid antigen test: potential to help reduce community spread?

Comparative evaluation of four rapid SARS-CoV-2 antigen detection tests using universal transport medium

Comparison of Rapid Antigen Tests for COVID-19